← Back

Wire · opportunities

Key facts: 2027 FDA bid, Phase 3 trials; analysts cut targets

Published

21 November 2026

Topic

opportunities

◆ Sectors

Drug Discovery

◆ Geography

United States

◆ Source

Read at tradingview.com →

◆ Verified

Fusion42 · 21 November 2026 · Fusion42 review

Celldex plans to seek FDA approval for barzolvolimab in chronic spontaneous urticaria in 2027, currently enrolling patients in Phase 3 trials for cold urticaria and symptomatic dermographism. Analysts have cut price targets but maintain positive outlooks with Barclays and HC Wainwright retaining Overweight and Buy ratings respectively.

This Wire brief sits within Fusion42's coverage of Drug Discovery.

◆ ◆ The Wire takeaway

You face a narrowing window as late-stage trial enrolment speeds toward 2027 FDA submission. Dial up your regulatory and market access teams now to prepare for pivotal approval and commercial rollout in dermatology treatments.

◆ Coverage

1 source · 21 Nov 2026

◆ Related on Wire

◆ Topics

Drug Discoveryfda-approvalphase-3-trialsdrug-developmentanalyst-target-cutscelldex